Pfizer Inc. (NYSE:PFE) insider Mikael Dolsten sold 69,699 shares of the stock in a transaction on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the completion of the sale, the insider now directly owns 120,784 shares of the company’s stock, valued at $4,419,486.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Mikael Dolsten also recently made the following trade(s):
- On Friday, March 2nd, Mikael Dolsten sold 13,986 shares of Pfizer stock. The stock was sold at an average price of $35.85, for a total transaction of $501,398.10.
Shares of Pfizer Inc. (PFE) traded down $0.16 during trading hours on Monday, hitting $36.61. 25,210,000 shares of the company’s stock were exchanged, compared to its average volume of 29,020,000. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The stock has a market cap of $217,930.00, a PE ratio of 20.92, a P/E/G ratio of 2.07 and a beta of 0.91. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47.
Pfizer declared that its Board of Directors has approved a share repurchase program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were paid a $0.34 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.71%. The ex-dividend date was Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 77.71%.
PFE has been the subject of a number of analyst reports. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, December 15th. UBS Group set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 target price for the company in a research note on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $39.40.
Several large investors have recently modified their holdings of PFE. Earnest Partners LLC bought a new stake in shares of Pfizer in the 4th quarter worth about $105,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer in the 2nd quarter worth about $103,000. First Dallas Securities Inc. bought a new stake in shares of Pfizer in the 4th quarter worth about $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in shares of Pfizer in the 4th quarter worth about $118,000. Finally, Delpha Capital Management LLC bought a new stake in shares of Pfizer in the 4th quarter worth about $126,000. 71.41% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Mikael Dolsten Sells 69,699 Shares of Pfizer Inc. (PFE) Stock” was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.themarketsdaily.com/2018/03/12/mikael-dolsten-sells-69699-shares-of-pfizer-inc-pfe-stock.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.